六分钟步行距离与当代左心室辅助装置接受者长期结局:ELEVATE注册研究
基于前瞻性多中心ELEVATE注册研究,分析194例HeartMate 3植入后6个月有六分钟步行距离(6MWD)的患者,按中位数350米分层。6MWD较短者年龄更大、合并症更多、生活质量更低,且主要出血、主要感染和肾功能不全发生率更高,但6MWD对死亡率、心衰复发或再住院无独立预后价值。
要点
- 6MWD较短与主要出血、感染和肾功能不全风险升高相关。
- 6MWD对死亡率、心衰复发或再住院无独立预后价值。
- 无循环支持心衰患者的6MWD预后价值不能外推至当前LVAD患者。
核心结论
- HM3植入后6个月较短的6MWD与部分不良事件风险升高相关,但对死亡率、心衰复发或再住院风险无预后价值。
研究设计与样本
- 前瞻性多中心ELEVATE注册研究,纳入194例HM3接受者,6个月时有可用6MWD数据,按中位数350米分层,使用Cox回归模型校正年龄和性别。
主要发现
- 6MWD低于中位数者年龄更大(57 vs. 52岁,p=0.002),合并症更多,生活质量更低。
- 6MWD与血红蛋白(r=0.20,p=0.006)和EQ-5D VAS(r=0.23,p=0.004)正相关,与NYHA分级负相关(r=-0.47,p<0.0001)。
- 6MWD低于中位数者主要出血(IRR 2.88,p<0.001)、主要感染(IRR 2.14,p<0.0001)和肾功能不全(IRR 4.78,p=0.033)发生率更高。
- Cox模型显示6MWD对死亡率无独立预后价值(HR 0.98,95%CI 0.96-1.01,p=0.26)。
- 按350米分层的Kaplan-Meier分析显示生存(log-rank p=0.379)、右心衰(p=0.334)和再住院(p=0.243)无显著差异,无血液相容性相关不良事件生存差异 marginally 显著(p=0.049)。
临床怎么用
- 6MWD可用于识别HM3接受者中不良事件风险较高的患者,但不宜作为死亡或再住院的预后判断工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to assess the prognostic value of Six-minute Walk Distance (6MWD) in stable HeartMate 3 (HM3) recipients. METHODS: Data from patients with available 6MWD at six months post-implant were obtained from the prospective, multicenter ELEVATE registry. Overall survival and adverse event rates were analyzed using Cox regression models adjusted for age and sex, with 6MWD as a continuous predictor, and stratified by median distance (350 m). RESULTS: 6MWD at six months was available in 194 HM3 recipients. Patients walking <median were older (57 vs. 52 years, p = 0.002), had more comorbidities, and reported lower quality of life. 6MWD correlated positively with hemoglobin (r = 0.20, p = 0.006) and EQ-5D VAS (r = 0.23, p = 0.004), and inversely with NYHA class (r=-0.47, p < 0.0001). Kaplan-Meier analyses of patients walking < > 350 m showed no significant differences in survival (log-rank p = 0.379), right heart failure (p = 0.334), or rehospitalization (p = 0.243), while survival free from hemocompatibility-related adverse events differed significantly, although marginally (p = 0.049). Cox models confirmed that 6MWD had no independent prognostic value for mortality (HR 0.98, 95% CI 0.96-1.01, p = 0.26) or secondary outcomes. However, patients with <median 6MWD experienced higher rates of major bleeding (IRR 2.88, p < 0.001), major infection (IRR 2.14, p < 0.0001), and renal dysfunction (IRR 4.78, p = 0.033). CONCLUSIONS: Shorter 6MWD six months after HM3 implantation was associated with a higher risk of some AEs but was not prognostic for mortality, HF recurrence, or rehospitalization risk. The prognostic value of 6MWD in HF patients without circulatory support cannot be extrapolated to patients treated with current LVADs.
引用
- Nielsen WH, Gustafsson F, Shaw S, et al. Six-minute walk distance and long-term outcomes in contemporary left ventricular assist device recipients: the ELEVATE Registry. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42726105. doi:10.1093/icvts/ivag241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。